Could less chemo be better? new trial aims to reduce treatment burden for brain lymphoma

NCT ID NCT04931368

Ongoing Disease control Sponsor: Klinikum Stuttgart Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase III trial tests whether a de-escalated (less intense) version of the standard MATRix chemotherapy regimen works as well for newly diagnosed primary CNS lymphoma. About 331 patients will receive either the standard four courses of MATRix or a reduced schedule with one course of rituximab/high-dose methotrexate followed by two courses of MATRix. The goal is to see if the gentler approach improves event-free survival while reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab and high-dose methotrexate (MATRix regimen)
What this could lead to: If successful, this could show that a less intense chemotherapy regimen works as well as the standard, reducing side effects for patients with primary CNS lymphoma.
What could go wrong: This is an early-stage Phase III trial with 331 participants. The de-escalated approach may prove less effective, and results may not apply to all patients. Chemotherapy still carries significant risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma of the central nervous system primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Klinikum Stuttgart

Stuttgart, Baden-Wurttemberg, 70174, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.